Tx Response No Different for Migalastat, Placebo in Fabry’s
Percentage of patients with response at six months doesn't differ with migalastat, placebo treatment
ESR1 Mutations Tied to Worse Survival in Metastatic Breast CA
ESR1 mutations prevalent in ER-positive metastatic breast cancer and linked to shorter survival
Many U.S. Hospitals Offer Language Services
Percentage of hospitals offering language services increases with level of need
Risk of Post-Op Opioid Abuse Deemed Low for Elderly Patients
Vast majority of patients use the meds short term to ease their pain
Recs Developed for Neoadjuvant Chemo in Ovarian Cancer
Guidance provided for clinicians treating women with stage IIIC or IV epithelial ovarian cancer
Western Diet May Contribute to Dense Breasts
In study, women who ate such a diet also had 46 percent higher risk of breast cancer
Many Americans Exposed to Toxic Chemicals in Drinking Water
Immunotoxicity of polyfluoroalkyl/perfluoroalkyl substances seen at current exposure levels
Guidance Needed for Frail Elderly With Nonmelanoma Skin Cancer
Integration of frailty-related items into current guidelines on nonmelanoma skin cancer is limited
Active Surveillance Prior to Systemic Tx Feasible in Renal CA
Shorter surveillance period for those with more IMDC adverse risk factors, more metastatic disease sites
Metabolic Factors May Contribute to Tx Resistance in Renal Cancer
Genes involved in metabolic and solute transport function linked to treatment failure in PD-L1+ RCC
